GTHX (g1therapeutics.com) Company Cash on Hand

G1 Therapeutics, Inc. (GTHX) provides bone marrow protection during chemotherapy, generating profit from the commercialization of its approved drug. A key event will be the $405 million acquisition by Pharmacosmos to secure the rights to Cosela. The biotech sector serves as a defensive asset due to its independence from macroeconomic trends. Free cash flow levels demonstrate liquidity, where 0.06 serves as the base parameter value.
Financial and market metric breakdowns for G1 Therapeutics, Inc. (GTHX)

G1 Therapeutics, Inc. (GTHX) is investing in environmental safety and closed-loop water purification systems to comply with ESG standards. This metric aggregates all liquid assets and equivalents, determining the company's ability to fund such capital-intensive developments. Daily monitoring eliminates the time lag of quarterly reporting, capturing the real level of financial stability. The current value of 0.06 reflects the actual strength of the balance sheet. Analyzing the cash flow chart allows investors to assess the balance between security and capital efficiency.